Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)
Tuchman, Sascha, Geyer, Susan, Nelson, Garth, Linden, Michael, Rosenberg, Aaron, Conlin, Alison, Ganguly, Siddhartha, Harichand-Herdt, Seema, Fanning, Suzanne, Carlisle, Destin, Banerjee, Rahul, Afrough, Aimaz, Mitsiades, Constantine, Hillengass, Jens, Suman, Vera Jean, Kennedy, C., Holstein, Sarah, Dinner, Shira, Voorhees, Peter, Usmani, Saad, Tuchman, Sascha, Geyer, Susan, Nelson, Garth, Linden, Michael, Rosenberg, Aaron, Conlin, Alison, Ganguly, Siddhartha, Harichand-Herdt, Seema, Fanning, Suzanne, Carlisle, Destin, Banerjee, Rahul, Afrough, Aimaz, Mitsiades, Constantine, Hillengass, Jens, Suman, Vera Jean, Kennedy, C., Holstein, Sarah, Dinner, Shira, Voorhees, Peter, Usmani, Saad

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2289-2289

10.1182/blood-2025-2289 Get It

Abstract Background: Multiple myeloma (MM) remains incurable, though key advances such as chimeric antigen receptor T-cells (CAR-T) and immunomodulatory agents, now evolving toward cereblon E3 ligase modulatory drugs (CELMoDs), have substantially improved the longevity and quality of life for patients (pts). Idecabtagene vicleucel (ide-cel) is a CAR-T targeting B-cell maturation antigen (BCMA), now US FDA-approved for pts who have received ≥2 prior lines of therapy including a proteasome inhibitor, immunomodulatory agent, and CD38 monoclonal antibody. Ide-cel was initially FDA-approved for ≥4 prior lines of therapy based on the KarMMa-1 study, which demonstrated a median progression-free survival (PFS) of 8.8 months across all cell doses and median overall survival (OS) of 19.4 months (Munshi et al., New Eng J Med 2021). Although promising, the fact that virtually all pts relapse post-ide-cel indicates that further progress is needed. To that end, iberdomide is an investigational CELMoD that in combination with dexamethasone has demonstrated a 30% response rate in early phase studies of triple class-refractory MM (Lonial et al., Lancet Haem 2022). Additionally, in laboratory-based correlative studies, iberdomide, at doses of ≤1 mg (well below the recommended phase 2 dose of 1.6 mg) was shown to augment immune function, including enhanced T-cell activation and cytotoxicity, and modulation of the cytokine milieu (Amatangelo et al., Cell Rep Med 2024). Iberdomide's combined properties of direct MM cytotoxicity and T-cell potentiation have clear, potential relevance to CAR-T clinically, providing the conceptual basis for the CADMIUM study (NCT06179888), exploring the effects of iberdomide as post-ide-cel maintenance therapy in MM. Study Design and Methods: This is a randomized phase II trial with a safety run-in to evaluate if treatment with iberdomide maintenance post-ide-cel can significantly improve PFS vs. standard of care (SOC) observation without therapy, in pts with relapsed/refractory MM with ≥4 prior lines of therapy, who have received ide-cel within 3 months of registration, and no evidence of MM progression or additional MM therapy since ide-cel. Pre-ide-cel iberdomide exposure is permissible but refractoriness is not. The safety run-in will confirm tolerability of the iberdomide dose to be carried forward, where doses to be tested include: iberdomide 1 mg orally on days 1-21 of a 28-day cycle (dose level 1; DL1) and iberdomide 0.7 mg on days 1-21 of a 28-day cycle (DL2). Dose-limiting toxicities (DLTs) include any of the following during the DLT period of a pt's first three months on iberdomide: prolonged Grade 3 non-hematologic toxicities, Grade 4 non-hematologic toxicities, prolonged Grade 4 neutropenia or thrombocytopenia, or any adverse event requiring iberdomide interruption for >4 weeks. Six pts will be enrolled onto DL1; if at most 1 of these pts has a DLT, DL1 will be carried forward to the randomized part of the study. Otherwise, 6 pts will be enrolled onto DL2. The randomized part of the trial will randomize 60 pts 1:1 to either iberdomide or SOC observation without therapy. A 1-sided log-rank test with α=0.15 has 81% power to detect a true hazard ratio (iberdomide/SOC) of 0.55 or less, corresponding to an improvement in median PFS to 16 vs. 8.8 months with SOC. One interim analysis for futility is planned. Secondary outcomes include OS, best response by International Myeloma Working Group (IMWG) criteria, and deepening of response, particularly conversion to complete response with a bone marrow minimal disease-negative state by Adaptive clonoSEQ (sensitivity 1e-6). Robust correlative studies will include CAR-T persistence, assays of T- and other immune cell function, and pathological analyses of whether BCMA expression on MM cells (prior to enrollment or at relapse) or other markers predict clinical outcomes. Study status: To date, 12 pts have been screened, with 7 pts enrolled on study as part of the safety run-in (1 patient replaced). Enrollment data will be updated at presentation. Notably, an amendment is forthcoming which will enhance correlative studies and broaden eligibility criteria to include patients who have received ≥2 prior lines of therapy, conforming with ide-cel's current FDA label. Study COI: BMS is supporting correlative studies. Study Support: U10CA180821, U10CA180882; BMS; U10CA180868 (NRG Oncology); http://acknowledgements.alliancefound.org
Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions
Abbott, Diana, Amorim, Ana , Houshyar, Samin , Adhikari, Arjab, Patel, Dilan A. , Wanjiku, Christopher, Bock, Allison M. , Any, Haya Al, Desai, Nidhi , Gupta, S. C. , Altomare, Nicole , Trotier, Daniel, Ricker, Edd , Hill, Brian T. , Gupta, Supriya , Major, Ajay , Abbott, Diana , Snyder, Jordan Andrew , Ahmed, Nausheen , Villasboas, José C. , Sharp, John, Voorhees, Timothy , Wallace, Danielle, Wagner, Charlotte B , Brooks, Taylor , Tsang, Mazie , Rajab, Mohamed , Iqbal, Madiha , Gupta, Supriya, Karmali, Reem , Pophali, Priyanka A. , Cherng, Hua‐Jay J. , Gupta, Arjun

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1798-1798

10.1182/blood-2025-1798 Get It

Abstract Background Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective for patients with relapsed/refractory (R/R) follicular lymphoma (FL), but differ in treatment schedules and associated “time toxicity,” or contact days spent physically interacting with the healthcare system. While contact days can be estimated from clinical trials, real-world data provides a more nuanced depiction of treatment-related time burden, which may guide treatment decision-making. The comparative time toxicity of CAR-T vs BsAb in R/R FL is not defined. Methods We conducted a multicenter retrospective study of adults with R/R grade 1-3A FL who received standard-of-care CAR-T (axi-cel, tisa-cel, liso-cel) or BsAb (mosunetuzumab, epcoritamab) in the third-line or later setting before Jan 1, 2025. Time toxicity was defined as outpatient or inpatient days with physical health care system contact, counting multiple visits on the same day as only one day. All days after treatment initiation were counted, regardless of disease progression, therapy completion, or relation to FL therapy. Median contact days over 1-year time horizon were compared, stratified by CAR-T vs BsAb, prior lines of therapy (LOT, 2 vs 3+), and time intervals (0-1, 1-3, 3-6, 6-9, and 9-12 months). Progression-free survival (PFS) and overall survival (OS) were calculated from day of CAR-T infusion or day 1, cycle 1 for BsAb. Cox regression and propensity matching (by age, ECOG, refractory to prior LOT, POD24) were used to assess predictors and survival associations with contact days. Results Among 209 patients from 15 U.S. academic centers, median age was 64, 37% were female, 61% received CAR-T (80% axi-cel, 7% liso-cel, 13% tisa-cel) and 39% BsAb (93% mosun, 7% epcor). Most had Grade 1-2 FL (72%), advanced stage (84%), and extranodal disease (51%). Median prior LOT was 3 (range 2-15), 41% were refractory to prior LOT, and 52% had POD24. Median number of BsAb doses was 10 (range 1-36). Patients receiving BsAb were significantly older (p<.01) and had higher CIRS comorbidity scores (p<.02) in both 2 and 3+ prior LOT cohorts, and had higher ECOG scores (p=.01) and were less likely to be refractory to prior LOT (p=.029) in 3+ LOT cohort. There were no differences in POD24 rates between CAR-T and BsAb. Median PFS for the entire cohort was 3.6 yrs; median OS was not reached. In the 2 prior LOT cohort (N=75), 60% received CAR-T and 40% BsAb. With median follow-up of 1.5 years, median PFS was not reached for CAR-T and 1.6 yrs for BsAb (p<.0001). In the 3+ prior LOT cohort (N=134), 62% received CAR-T and 38% BsAb. With median follow-up of 2 yrs, median PFS was 3.6 yrs for CAR-T and 1.6 yrs for BsAb (p=.0044). In propensity matched analysis, PFS was shorter for BsAb in both 2 LOT (HR 9.0, 95% CI 1.14-71.04, p=.037) and 3+ LOT (HR 3.25, 95% CI 1.06-9.97, p=.039) cohorts as compared to CAR-T. There were no significant differences in OS between CAR-T and BsAb. Median contact days were significantly higher for CAR-T vs BsAb in the 0-1 month interval: 19 vs 8 days in 2 LOT (p<.0001) and 18 vs 7 days in 3+ LOT (p<.0001) cohorts. There were no differences in contact days between CAR-T vs BsAb in subsequent time intervals. Over 1 year, CAR-T had significantly more time toxicity than BsAb: median 51 vs 36 contact days in 2 LOT (p<.0001) and 64 vs 38 days in 3L+ LOT (p<.0001) cohorts; these remained significant in the matched analysis. B symptoms (p=.04) and Grade ≥3 cytopenias (p=.007) were associated with higher contact days in 3+ LOT cohort in univariable analysis. Higher contact days were associated with inferior PFS (HR 1.01, 95% CI 1.00-1.02, p=.032) and OS (HR 1.01, 95% CI 1.00-1.02, p=.038) in 3+ LOT cohort regardless of treatment type. Discussion In this large real-world cohort of patients with R/R FL, CAR-T therapy resulted in better PFS but more time toxicity over the first year as compared to BsAb therapy. Excess time toxicity from CAR-T was driven by more contact days in the first month of treatment. This study provides benchmark data for counseling patients about expected time burden of CAR-T (51-64 days) and BsAb (36-38 days) over the first year of these therapies. Further, with superior PFS of CAR-T in this study and minimal impact of time toxicity on survival outcomes, these data can be used to better support shared decision-making in R/R FL by addressing patient preferences regarding both contact days as well as duration of disease control.
KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)
Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Muffly, Lori, Shah, Bijal, Aldoss, Ibrahim, Muffly, Lori , Muffly, Lori , Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Shah, Bijal, Aldoss, Ibrahim

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3365-3365

10.1182/blood-2025-3365 Get It

Abstract Introduction: Brexu-cel is a highly effective treatment for R/R B-ALL, with complete responses achieved in 71% of patients (pts) treated in the pivotal ZUMA-3 trial. Patients with B-ALL with high-risk (HR) genetics are known to have inferior outcomes with chemotherapy, but little is known about the influence of HR ALL genetics on responses to chimeric antigen receptor (CAR)-T in adults. In this study, we assessed the impact of HR ALL genetics on outcomes in a large cohort of adult patients treated with brexu-cel for R/R Philadelphia chromosome (Ph)-negative B-ALL. Methods: Patient characteristics and outcomes were obtained from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) database which includes data from 40 U.S. centers. NCCN guidelines (NCCN Guidelines in Oncology, ALL v2.2025) were used to define HR B-ALL genetics; lack of HR genetics was defined as standard-risk (SR). The primary outcome was event-free survival (EFS), defined as lack of response, disease progression, or death from any cause. Secondary outcomes were overall survival (OS), relapse free survival (RFS) and response rates including complete response (CR), CR incomplete count recovery (CRi), measurable residual disease negative CR (MRD-) by flow or NGS and progressive disease (PD). Multivariable models were adjusted for age, pre-infusion blast percentage, prior allo-HCT, and post CAR-T allo-HCT (modeled as a time-varying covariate). Results: The cohort included 286 pts: 169 with HR and 117 with SR B-ALL. The HR cohort included TP53m (n=24, 14%), KMT2Ar (n=16, 9%), CRLF2r (n=65, 39%) and other HR genetics such as JAK2 and other Ph-like, IKZF1, complex cytogenetics (n=64, 38%). Relative to SR pts, HR pts were more commonly Hispanic (50% vs 28%). HR and SR pts had similar disease burden pre-apheresis (>5% blasts: 58% vs 53%), prior blinatumomab (60% vs 58%), prior inotuzumab (42% vs 46%), and prior allo HCT (27% vs 37%). The presence of CNS disease (11% HR vs 12% SR) and extramedullary disease (EMD, 22% HR vs 29% SR) at apheresis was also similar. CR/CRi was achieved in 90.5% of evaluable HR pts (n=147) and 90.2% of evaluable SR pts (n=102); MRD- rates were also similar between HR and SR pts at 78.9% and 78.2% respectively. In unadjusted analyses, EFS did not significantly differ between HR pts (median 9.6 mos; 1-yr: 46%, 95% CI 38%-54%) and SR pts (median 11.6 mos; 1-yr: 48%, 95% CI 38%- 58%). Median RFS (HR: 12.2 mos, SR: 13.3 mos) and median OS (HR: 22.4 mos, SR: 21.0 mos) were also similar. Multivariable models demonstrated no significant associations between HR B-ALL and EFS (HR 1.09, 95% CI 0.73-1.63), RFS (HR 1.13, 95% CI 0.71-1.80), or OS (HR 0.96, 95% CI 0.62- 1.48) relative to SR ALL. 28% of HR patients and 21% of SR patients underwent consolidative allo-HCT. Among the HR subgroup, CR/CRi rate was lowest in KMT2Ar (71%) relative to TP53m (95%), CRLF2r (95%), and other HR genetics (89%). The median EFS was lowest in KMT2Ar (4.1 mos), followed by TP53m (6.9 mos), CRLF2r (11.6 mos), and other HR (11.1 mos). Median OS was also lowest in KMT2Ar (6.8 mos) vs 22.4 mos in TP53m and not reached in CRLF2r or other HR. PD was highest in KMT2Ar pts (29%), as compared to 11% HR other, 10% SR, and 5% TP53 and CRLF2r. The rate of relapse among those that achieved CR across the groups was similar and ranged between 28% -40%. Rates of CD19 negative relapse were similar between all subgroups (13%-15%), however 21% of KMT2A pts underwent myeloid transformation as compared 0% for TP53 and CRLF2 pts, and 2% among other HR and SR pts. 25% of KMT2Ar patients underwent consolidative allo-HCT as compared to 32% CRLF2 pts, 29% TP53 pts, 25% other HR pts and 21% SR pts. Multivariable models evaluating the different genomic subgroups demonstrated that relative to SR B-ALL, only KMT2Ar was associated with inferior OS (HR 3.17, 95% CI 1.53-6.58, p=0020). No associations were seen between HR subgroups and EFS. Conclusion: To our knowledge, this analysis represents the largest examination of adult B-ALL recipients of CAR-T assessed by genomic risk group. We found that response rates and survival outcomes following brexu-cel were similar among HR and SR B-ALL pts, including pts with TP53m and CRLF2r. However, pts with KMT2Ar had lower response rates and dismal EFS and OS, with higher rates of PD and myeloid transformation at relapse, suggesting that alternative strategies are necessary to improve outcomes for patients with R/R KMT2Ar B-ALL.
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Rutherford, Sarah C. , Ansell, Stephen M. , Armand, Philippe , Leonard, John P. , Smith, Sonali M. , Timmerman, John M. , Zelenetz, Andrew D. , Gutierrez, Meghan, Béguelin, Wendy , Nadel, Bertrand, Pasqualucci, Laura , LaCasce, Ann S. , Rutherford, Sarah C , Smith, Sonali M , Zelenetz, Andrew D , Béguelin, Wendy , Casulo, Carla , Cerhan, James R , Kridel, Robert , Link, Brian K , Maurer, Matthew , Radtke, Andrea J , Luttwak, Efrat , Salles, Gilles A , Pasqualucci, Laura , LaCasce, Ann Steward , Merryman, Reid W. , Nastoupil, Loretta J. , Casulo, Carla , Cerhan, James R. , Green, Michael Richard , Kahl, Brad S. , Link, Brian K. , Maurer, Matthew J. , Luttwak, Efrat , Salles, Gilles , Sehn, Laurie H.

Mayo Clinic

Blood Advances | December 3, 2025 | Volume: 10 | Issue: 5 | Pages: 1591-1602

10.1182/bloodadvances.2025018079 | PMID 41337699 Get It

Abstract Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation’s biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.
Building Resilient Clinicians: Lessons From Palliative Care Training for the Heart Failure Community
Godfrey, Sarah , Drazner, Mark H. , Godfrey, Sarah

Mayo Clinic

Circulation: Heart Failure | December 3, 2025 | Volume: 19 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.125.013403 | PMID 41332419 Get It

Predicted Breast Cancer Risk after Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Analysis of a Multi-Institutional Children’s Oncology Group Trial
Milgrom, Sarah A. , Dama, Hitesh, Renfro, Lindsay A. , Wu, Yue , Meyer, Ilan H. , Jeeva, Meenakshi , Punnett, Angela , Charpentier, A-M, Keller, Frank G. , Kelly, Kara M. , Paganetti, Harald , Meyer, I, Parsons, Susan K. , Charpentier, A-M, Lo, Acy , Vega, Raymond B. Mailhot , Hoppe, Bradford S. , Castellino, Sharon M. , Hodgson, David

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812961 Get It

Multi-modality Artificial Intelligence for Involved-Site Radiation Therapy: Clinical Target Volume Delineation in High-Risk Pediatric Hodgkin Lymphoma
Milgrom, Sarah A. , Charpentier, AM, LaRiviere, M.J., Kelly, Kara M. , Hodgson, Darren , Castellino, S, Tie, Xin , Hodgson, David C. , Cho, S Y, Hodgson, D, Castellino, Sharon M. , Hoppe, Bradford S. , Bradshaw, Tyler

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812957 Get It

Prognostic value of 18F-FDG PET/CT volumetric parameters in childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL): a systematic review from the international SEARCH group (Staging, Evaluation and Response Criteria Harmonization)
Castellino, S, Dieckmann, Karin, Kelly, Kara M. , Kurch, Lars , Lai, Hollie , Mauz-Koerholz, Christine, McCarten, Kathleen M. , Steglich, J., Stoevesandt, Dietrich, Voss, Stephan D. , Milgrom, Sarah A. , Gowdy, Claire , Flerlage, Jamie E. , Seelisch, Jennifer , Palese, M, Bradshaw, Tyler , Castellino, Sharon M. , Cho, Steve K. , Hoppe, Bradford S. , Howard, Scott C. , Lopci, Egesta , Lucas, John T. , Mauz‐Körholz, Christine , Pandit-Taskar, Neeta D. , Schöder, Heiko

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812922 Get It

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy to Immuno-oncology for Children & Adults with Newly Diagnosed Stage I and II Hodgkin Lymphoma
Renfro, Lindsay A. , Keller, Frank G. , DuVall, Aaron, Henderson, Tara O. , Cho, S. Y., Milgrom, Sarah A. , Roth, Lisa , LaCasce, Ann S. , Kahn, J M, Parson, Susan K., Kelly, Kara M. , Seelisch, Jennifer , Hu, Boyu , Wu, Yonghui , Hoppe, Bradford S. , Grover, Natalie S. , Yao, Song , Khan, Nadia , Vega, Raymond B. Mailhot , Hinds, Pamela S. , Allen, P B, Evens, Andrew M. , Schöder, Heiko , Castellino, Sharon M.

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812908 Get It